Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you ...

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term ...

The latest trading day saw Pfizer (PFE) settling at $26.8, representing a -1.87% change from its previous close.

The healthcare giant has been investing heavily in its future growth.

Pharmaceutical giant Pfizer is set to cut more than 100 jobs at its Ringaskiddy, Co Cork, plant in the final quarter of 2026, ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February.